Sage Therapeutics (NASDAQ:SAGE) Cut to Sell at StockNews.com

Sage Therapeutics (NASDAQ:SAGE) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Thursday.

A number of other analysts have also weighed in on the stock. TD Cowen lowered shares of Sage Therapeutics from a “buy” rating to a “hold” rating and decreased their target price for the stock from $16.00 to $10.00 in a report on Tuesday, July 30th. Scotiabank decreased their target price on shares of Sage Therapeutics from $17.00 to $14.00 and set a “sector outperform” rating on the stock in a report on Wednesday. Oppenheimer cut their price target on shares of Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Wednesday. Royal Bank of Canada cut shares of Sage Therapeutics from an “outperform” rating to a “sector perform” rating and cut their price target for the stock from $10.00 to $4.00 in a research note on Friday, October 4th. Finally, Truist Financial cut their price target on shares of Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating for the company in a research note on Wednesday. Three analysts have rated the stock with a sell rating, seventeen have given a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $12.89.

Sage Therapeutics Stock Down 0.5 %

NASDAQ SAGE opened at $6.05 on Thursday. The company’s 50 day moving average is $7.44 and its 200-day moving average is $9.95. Sage Therapeutics has a 12-month low of $5.84 and a 12-month high of $28.26. The firm has a market cap of $370.10 million, a P/E ratio of -1.08 and a beta of 0.91.

Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.52) by ($0.01). The firm had revenue of $11.87 million for the quarter, compared to the consensus estimate of $10.80 million. Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. The business’s revenue was up 337.1% on a year-over-year basis. During the same period last year, the company posted ($2.81) EPS. Equities analysts expect that Sage Therapeutics will post -6.43 EPS for the current year.

Institutional Investors Weigh In On Sage Therapeutics

Large investors have recently added to or reduced their stakes in the company. Headlands Technologies LLC grew its holdings in Sage Therapeutics by 245.3% in the 2nd quarter. Headlands Technologies LLC now owns 3,916 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 2,782 shares during the last quarter. Lazard Asset Management LLC bought a new stake in Sage Therapeutics in the 1st quarter worth $127,000. Virtu Financial LLC bought a new stake in Sage Therapeutics in the 1st quarter worth $187,000. China Universal Asset Management Co. Ltd. grew its holdings in Sage Therapeutics by 66.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company’s stock worth $85,000 after acquiring an additional 4,672 shares during the last quarter. Finally, Quest Partners LLC grew its holdings in Sage Therapeutics by 14.5% in the 2nd quarter. Quest Partners LLC now owns 11,763 shares of the biopharmaceutical company’s stock worth $128,000 after acquiring an additional 1,486 shares during the last quarter. Institutional investors own 99.22% of the company’s stock.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.